{"id":"NCT01210716","sponsor":"Fenwal, Inc.","briefTitle":"Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device","officialTitle":"Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2010-09-28","resultsPosted":"2013-09-23","lastUpdate":"2013-09-23"},"enrollment":37,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":null},"conditions":["Autoimmune Diseases","Renal Disorders","Hematologic Disorders","Oncologic Disorders"],"interventions":[{"type":"DEVICE","name":"Therapeutic plasma exchange","otherNames":["TPE"]}],"arms":[{"label":"AMICUS Therapeutic plasma exchange, TPE","type":"EXPERIMENTAL"},{"label":"Spectra Therapeutic plasma exchange, TPE","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the use of the AMICUS device in patients where Therapeutic Plasma Exchange (TPE) is prescribed by their physicians.","primaryOutcome":{"measure":"Percent Efficiency of Plasma Removal During the Therapeutic Plasma Exchange Procedure","timeFrame":"After completion of the TPE procedure.","effectByArm":[{"arm":"AMICUS (Test)","deltaMin":81.9,"sd":null},{"arm":"Spectra (Control)","deltaMin":75.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":37},"commonTop":["Paresthesia","Dizzy/Light-Headed","Nausea","Fatigue","Infiltration"]}}